Literature DB >> 2444694

The effect of tranilast of the generation of reactive oxygen species.

Y Miyachi1, S Imamura, Y Niwa.   

Abstract

The relative in vitro antioxidant efficacy of tranilast, a new orally active anti-allergic agent, was examined by studying its effects on the generation of reactive oxygen species (ROS) using zymosan-stimulated polymorphonuclear leukocytes and the cell-free, xanthine-xanthine oxidase system. The species investigated were superoxide radical anion (O2-), hydrogen peroxide (H2O2) and hydroxyl radical (OH.). At concentrations comparable to therapeutic blood levels, tranilast reduced both H2O2 and OH. levels. The inhibitory effect of tranilast was dose-dependent and all ROS levels examined were significantly decreased at the concentration of 100 micrograms/ml. This antioxidant effect of tranilast appeared to stem from its capability to scavenge ROS because the suppression of ROS was observed in both ROS generation systems at higher concentrations, even though the possibility existed that tranilast directly inhibited nicotineamide adenine dinucleotide phosphate oxidase and/or xanthine oxidase activity. This unique anti-inflammatory pharmacological activity of tranilast suggests its potential clinical application for allergic diseases complicated with inflammation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2444694     DOI: 10.1248/bpb1978.10.255

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  7 in total

1.  Inhibitory mechanism of tranilast in human coronary artery smooth muscle cells proliferation, due to blockade of PDGF-BB-receptors.

Authors:  S Watanabe; A Matsuda; Y Suzuki; K Kondo; Y Ikeda; H Hashimoto; K Umemura
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  Protection against ovariectomy-induced bone loss by tranilast.

Authors:  Tien Van Phan; Ke Ke; Ok-Joo Sul; Yun-Kyung Park; Kack-Kyun Kim; Yeon-Soo Cho; Hun-Taeg Chung; Hye-Seon Choi
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

3.  Uricosuric targets of tranilast.

Authors:  Asim K Mandal; Adriana Mercado; Andria Foster; Kambiz Zandi-Nejad; David B Mount
Journal:  Pharmacol Res Perspect       Date:  2017-02-06

Review 4.  NLRP3 Inflammasome in Vascular Disease: A Recurrent Villain to Combat Pharmacologically.

Authors:  Ainara González-Moro; Inés Valencia; Licia Shamoon; Carlos Félix Sánchez-Ferrer; Concepción Peiró; Fernando de la Cuesta
Journal:  Antioxidants (Basel)       Date:  2022-01-29

5.  Opposite effect of mast cell stabilizers ketotifen and tranilast on the vasoconstrictor response to electrical field stimulation in rat mesenteric artery.

Authors:  Esther Sastre; Laura Caracuel; Fabiano E Xavier; Gloria Balfagón; Javier Blanco-Rivero
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

6.  Tranilast increases vasodilator response to acetylcholine in rat mesenteric resistance arteries through increased EDHF participation.

Authors:  Fabiano E Xavier; Javier Blanco-Rivero; Esther Sastre; Laura Caracuel; María Callejo; Gloria Balfagón
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

Review 7.  Biological Activities, Health Benefits, and Therapeutic Properties of Avenanthramides: From Skin Protection to Prevention and Treatment of Cerebrovascular Diseases.

Authors:  Andrea Perrelli; Luca Goitre; Anna Maria Salzano; Andrea Moglia; Andrea Scaloni; Saverio Francesco Retta
Journal:  Oxid Med Cell Longev       Date:  2018-08-23       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.